{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T04:00:58Z","timestamp":1774843258146,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Sichuan Science and Technology Program","award":["2022YFS0622"],"award-info":[{"award-number":["2022YFS0622"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"DOI":"10.1007\/s12026-026-09767-1","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T02:35:30Z","timestamp":1774838130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Using B-cell-targeting drugs to achieve marked efficacy in anti-signal recognition particle myopathy: two case reports"],"prefix":"10.1007","volume":"74","author":[{"given":"Zhuoyao","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiongyan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-3738","authenticated-orcid":false,"given":"Anji","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"issue":"1","key":"9767_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","volume":"28","author":"Y Allenbach","year":"2018","unstructured":"Allenbach Y, Mammen AL, Benveniste O, Stenzel W, Immune-Mediated Necrotizing Myopathies Working G. 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14\u201316 October 2016. Neuromuscul Disord. 2018;28(1):87\u201399. https:\/\/doi.org\/10.1016\/j.nmd.2017.09.016.","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"9767_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41584-020-00515-9","volume":"16","author":"Y Allenbach","year":"2020","unstructured":"Allenbach Y, Benveniste O, Stenzel W, Boyer O. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol. 2020;16(12):689\u2013701. https:\/\/doi.org\/10.1038\/s41584-020-00515-9.","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"9767_CR3","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/acr.20219","volume":"62","author":"R Valiyil","year":"2010","unstructured":"Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res. 2010;62(9):1328\u201334. https:\/\/doi.org\/10.1002\/acr.20219.","journal-title":"Arthritis Care Res"},{"key":"9767_CR4","doi-asserted-by":"publisher","unstructured":"Ma X, Bu B-T. Anti-SRP immune-mediated necrotizing myopathy: a critical review of current concepts. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.1019972.","DOI":"10.3389\/fimmu.2022.1019972"},{"key":"9767_CR5","doi-asserted-by":"publisher","unstructured":"Targoff INJA, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 1990;91361\u201370. https:\/\/doi.org\/10.1002\/art.1780330908.","DOI":"10.1002\/art.1780330908"},{"issue":"6","key":"9767_CR6","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.ajpath.2012.08.033","volume":"181","author":"C Preusse","year":"2012","unstructured":"Preusse C, Goebel HH, Held J, Wengert O, Scheibe F, Irlbacher K, et al. Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile. Am J Pathol. 2012;181(6):2161\u201371. https:\/\/doi.org\/10.1016\/j.ajpath.2012.08.033.","journal-title":"Am J Pathol"},{"issue":"6","key":"9767_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/rheumatology\/kep078","volume":"48","author":"H Gunawardena","year":"2009","unstructured":"Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford). 2009;48(6):607\u201312. https:\/\/doi.org\/10.1093\/rheumatology\/kep078.","journal-title":"Rheumatology (Oxford)"},{"key":"9767_CR8","doi-asserted-by":"publisher","unstructured":"Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology20. 2007;21:2008\u201319. https:\/\/doi.org\/10.1212\/01.WNL.0000291619.17160.b8.","DOI":"10.1212\/01.WNL.0000291619.17160.b8"},{"key":"9767_CR9","unstructured":"Huajie Gao JL, Mengge Y. Mengcui Gui,Suqiong Ji,Bitao Bu,Yue Li. Telitacicept add-on therapy in refractory idiopathic inflammatory myopathy: insights from a pilot study. Rheumatology (Oxford). 2024:M 39495163."},{"key":"9767_CR10","doi-asserted-by":"publisher","first-page":"175628642199891","DOI":"10.1177\/1756286421998918","volume":"14","author":"A Xiong","year":"2021","unstructured":"Xiong A, Yang G, Song Z, Xiong C, Liu D, Shuai Y, et al. Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series. Ther Adv Neurol Disord. 2021;14:1756286421998918. https:\/\/doi.org\/10.1177\/1756286421998918.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"9767_CR11","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/rheumatology\/kev444","volume":"55","author":"R Aggarwal","year":"2016","unstructured":"Aggarwal R, Oddis CV, Goudeau D, Koontz D, Qi Z, Reed AM, et al. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. Rheumatology (Oxford). 2016;55(6):991\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/kev444.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"9767_CR12","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1093\/rheumatology\/kep027","volume":"48","author":"BR Whelan","year":"2009","unstructured":"Whelan BR, Isenberg DA. Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. Rheumatology (Oxford). 2009;48(5):594\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/kep027.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"9767_CR13","doi-asserted-by":"publisher","first-page":"102993","DOI":"10.1016\/j.autrev.2021.102993","volume":"21","author":"G Merlonghi","year":"2022","unstructured":"Merlonghi G, Antonini G, Garibaldi M. Immune-mediated necrotizing myopathy (IMNM): A myopathological challenge. Autoimmun Rev. 2022;21(2):102993. https:\/\/doi.org\/10.1016\/j.autrev.2021.102993.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"9767_CR14","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3899\/jrheum.120682","volume":"40","author":"IN Lazarou","year":"2013","unstructured":"Lazarou IN, Guerne PA. Classification, diagnosis, and management of idiopathic inflammatory myopathies. J Rheumatol. 2013;40(5):550\u201364. https:\/\/doi.org\/10.3899\/jrheum.120682.","journal-title":"J Rheumatol"},{"issue":"6","key":"9767_CR15","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1093\/rheumatology\/keab166","volume":"60","author":"AGS Oldroyd","year":"2021","unstructured":"Oldroyd AGS, Allard AB, Callen JP, Chinoy H, Chung L, Fiorentino D, et al. A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology (Oxford). 2021;60(6):2615\u201328. https:\/\/doi.org\/10.1093\/rheumatology\/keab166.","journal-title":"Rheumatology (Oxford)"},{"key":"9767_CR16","doi-asserted-by":"publisher","unstructured":"Dalakas MC. Invited article: inhibition of B cell functions: implications for neurology Neurology. 2008(23):2252\u201360. https:\/\/doi.org\/10.1212\/01.wnl.0000313840.27060.bf.","DOI":"10.1212\/01.wnl.0000313840.27060.bf"},{"issue":"10","key":"9767_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/ncpneuro0901","volume":"4","author":"MC Dalakas","year":"2008","unstructured":"Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol. 2008;4(10):557\u201367. https:\/\/doi.org\/10.1038\/ncpneuro0901.","journal-title":"Nat Clin Pract Neurol"},{"issue":"5","key":"9767_CR18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s11882-014-0434-8","volume":"14","author":"H Eibel","year":"2014","unstructured":"Eibel H, Kraus H, Sic H, Kienzler AK, Rizzi M. B cell biology: an overview. Curr Allergy Asthma Rep. 2014;14(5):434. https:\/\/doi.org\/10.1007\/s11882-014-0434-8.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"5","key":"9767_CR19","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s10067-020-04996-7","volume":"39","author":"L Bergantini","year":"2020","unstructured":"Bergantini L, d\u2019Alessandro M, Cameli P, Vietri L, Vagaggini C, Perrone A, et al. Effects of rituximab therapy on B cell differentiation and depletion. Clin Rheumatol. 2020;39(5):1415\u201321. https:\/\/doi.org\/10.1007\/s10067-020-04996-7.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"9767_CR20","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/acr.20219","volume":"62","author":"R Valiyil","year":"2010","unstructured":"Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher\u2010Stine L. Rituximab therapy for myopathy associated with anti\u2013signal recognition particle antibodies: A case series. Arthritis Care Res. 2010;62(9):1328\u201334. https:\/\/doi.org\/10.1002\/acr.20219.","journal-title":"Arthritis Care Res"},{"issue":"6","key":"9767_CR21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3899\/jrheum.171495","volume":"46","author":"O Landon-Cardinal","year":"2019","unstructured":"Landon-Cardinal O, Allenbach Y, Soulages A, Rigolet A, Hervier B, Champtiaux N, et al. Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy. J Rhuematol. 2019;46(6):623\u20137. https:\/\/doi.org\/10.3899\/jrheum.171495.","journal-title":"J Rhuematol"},{"issue":"1","key":"9767_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.smim.2007.12.006","volume":"20","author":"I Sanz","year":"2008","unstructured":"Sanz I, Wei C, Lee FE-H, Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol. 2008;20(1):67\u201382. https:\/\/doi.org\/10.1016\/j.smim.2007.12.006.","journal-title":"Semin Immunol"},{"key":"9767_CR23","doi-asserted-by":"publisher","unstructured":"Madanchi N, Bitzan M, Takano T. Rituximab in minimal change disease. Can J Kidney Health Disease. 2017;4. https:\/\/doi.org\/10.1177\/2054358117698667.","DOI":"10.1177\/2054358117698667"},{"key":"9767_CR24","doi-asserted-by":"publisher","unstructured":"Rezahosseini O, M\u00f8ller DL, Knudsen AD, S\u00f8rensen SS, Perch M, Gustafsson F, et al. Use of T cell mediated immune functional assays for adjustment of immunosuppressive or anti-infective agents in solid organ transplant recipients: a systematic review. Front Immunol. 2020;11. https:\/\/doi.org\/10.3389\/fimmu.2020.567715.","DOI":"10.3389\/fimmu.2020.567715"},{"issue":"3","key":"9767_CR25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s11940-012-0172-y","volume":"14","author":"A Nath","year":"2012","unstructured":"Nath A, Berger JR. Complications of Immunosuppressive\/Immunomodulatory Therapy in Neurological Diseases. Curr Treat Options Neurol. 2012;14(3):241\u201355. https:\/\/doi.org\/10.1007\/s11940-012-0172-y.","journal-title":"Curr Treat Options Neurol"},{"issue":"2","key":"9767_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1128\/cmr.00013-12","volume":"25","author":"A Morris","year":"2012","unstructured":"Morris A, Norris KA. Colonization by Pneumocystis jirovecii and Its Role in Disease. Clin Microbiol Rev. 2012;25(2):297\u2013317. https:\/\/doi.org\/10.1128\/cmr.00013-12.","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"9767_CR27","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s13311-022-01206-x","volume":"19","author":"V Redenbaugh","year":"2022","unstructured":"Redenbaugh V, Flanagan EP. Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD. Neurotherapeutics. 2022;19(3):808\u201322. https:\/\/doi.org\/10.1007\/s13311-022-01206-x.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"9767_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","volume":"58","author":"Y Fan","year":"2022","unstructured":"Fan Y, Gao D, Zhang Z. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus. Drugs Today (Barc). 2022;58(1):23\u201332. https:\/\/doi.org\/10.1358\/dot.2022.58.1.3352743.","journal-title":"Drugs Today (Barc)"},{"issue":"14","key":"9767_CR29","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S, Telitacicept. First Approval Drugs. 2021;81(14):1671\u20135. https:\/\/doi.org\/10.1007\/s40265-021-01591-1.","journal-title":"First Approval Drugs"},{"issue":"1","key":"9767_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/bcp.12908","volume":"82","author":"X Chen","year":"2016","unstructured":"Chen X, Zhao Q, Hou Y, Jiang J, Zhong W, Wang W, et al. Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS\/APRIL fusion protein, in patients with rheumatoid arthritis. Br J Clin Pharmacol. 2016;82(1):41\u201352. https:\/\/doi.org\/10.1111\/bcp.12908.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"9767_CR31","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/jcph.686","volume":"56","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Chen X, Hou Y, Jiang J, Zhong W, Yao X, et al. Pharmacokinetics, Pharmacodynamics, Safety, and Clinical Activity of Multiple Doses of RCT-18 in Chinese Patients With Systemic Lupus Erythematosus. J Clin Pharmacol. 2016;56(8):948\u201359. https:\/\/doi.org\/10.1002\/jcph.686.","journal-title":"J Clin Pharmacol"},{"issue":"Pt 8","key":"9767_CR32","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/brain\/awh518","volume":"128","author":"R Raju","year":"2005","unstructured":"Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain. 2005;128(Pt 8):1887\u201396. https:\/\/doi.org\/10.1093\/brain\/awh518.","journal-title":"Brain"},{"key":"9767_CR33","doi-asserted-by":"publisher","first-page":"105704","DOI":"10.1016\/j.ejps.2021.105704","volume":"159","author":"X Yao","year":"2021","unstructured":"Yao X, Ren Y, Zhao Q, Chen X, Jiang J, Liu D, et al. Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS\/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. Eur J Pharm Sci. 2021;159:105704. https:\/\/doi.org\/10.1016\/j.ejps.2021.105704.","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"9767_CR34","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","volume":"43","author":"F Shi","year":"2021","unstructured":"Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y. Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol. 2021;43(6):666\u201373. https:\/\/doi.org\/10.1080\/08923973.2021.1973493.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"9767_CR35","doi-asserted-by":"publisher","unstructured":"Luca NJAA, Hawkins C, Feldman BM. Anti-signal recognition particle-positive juvenile polymyositis successfully treated with rituximab. J Rheumatol. 2012;71483\u20135. https:\/\/doi.org\/10.3899\/jrheum.111592.","DOI":"10.3899\/jrheum.111592"},{"key":"9767_CR36","doi-asserted-by":"publisher","unstructured":"Mamarabadi MBA, Leitch M, Hsu V, Kanduri JS, Chen S. Case of anti-single recognition particle-mediated necrotizing myopathy after influenza vaccination. J Clin Neuromuscul Dis 2018(4):211\u20136. https:\/\/doi.org\/10.1097\/CND.0000000000000208.","DOI":"10.1097\/CND.0000000000000208"},{"issue":"5","key":"9767_CR37","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1136\/practneurol-2018-002168","volume":"19","author":"P Mehta","year":"2019","unstructured":"Mehta P, Dorsey-Campbell R, Dassan P, Nelson-Piercy C, Viegas S. Difficult case: rituximab in anti-SRP antibody myositis in pregnancy. Pract Neurol. 2019;19(5):444\u20136. https:\/\/doi.org\/10.1136\/practneurol-2018-002168.","journal-title":"Pract Neurol"},{"issue":"1","key":"9767_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12969-017-0205-x","volume":"15","author":"EL Binns","year":"2017","unstructured":"Binns EL, Moraitis E, Maillard S, Tansley S, McHugh N, Jacques TS, et al. Effective induction therapy for anti-SRP associated myositis in childhood: A small case series and review of the literature. Pediatr Rheumatol Online J. 2017;15(1):77. https:\/\/doi.org\/10.1186\/s12969-017-0205-x.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"5","key":"9767_CR39","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.nmd.2006.03.002","volume":"16","author":"JB Arlet","year":"2006","unstructured":"Arlet JB, Dimitri D, Pagnoux C, Boyer O, Maisonobe T, Authier FJ, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord. 2006;16(5):334\u20136. https:\/\/doi.org\/10.1016\/j.nmd.2006.03.002.","journal-title":"Neuromuscul Disord"},{"key":"9767_CR40","doi-asserted-by":"publisher","first-page":"777502","DOI":"10.3389\/fimmu.2021.777502","volume":"12","author":"BB Cui","year":"2021","unstructured":"Cui BB, Tian YR, Ma XY, Yin G, Xie Q. Belimumab for Immune-Mediated Necrotizing Myopathy Associated With Anti-SRP Antibodies: A Case Report and Retrospective Review of Patients Treated With Anti-B-Cell Therapy in a Single Center and Literature. Front Immunol. 2021;12:777502. https:\/\/doi.org\/10.3389\/fimmu.2021.777502.","journal-title":"Front Immunol"},{"issue":"7","key":"9767_CR41","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s00296-021-04904-5","volume":"42","author":"C Mazeda","year":"2022","unstructured":"Mazeda C, Cunha R, Ferreira PG, Barcelos A, Aguiar R. Myopathy associated with anti-signal recognition particle antibodies with pulmonary involvement and response to rituximab. Rheumatol Int. 2022;42(7):1265\u20139. https:\/\/doi.org\/10.1007\/s00296-021-04904-5.","journal-title":"Rheumatol Int"},{"issue":"4","key":"9767_CR42","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s13311-018-00676-2","volume":"15","author":"ER McGrath","year":"2018","unstructured":"McGrath ER, Doughty CT, Amato AA. Autoimmune Myopathies: Updates on Evaluation and Treatment. Neurotherapeutics. 2018;15(4):976\u201394. https:\/\/doi.org\/10.1007\/s13311-018-00676-2.","journal-title":"Neurotherapeutics"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09767-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-026-09767-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09767-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T02:35:35Z","timestamp":1774838135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-026-09767-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9767"],"URL":"https:\/\/doi.org\/10.1007\/s12026-026-09767-1","relation":{},"ISSN":["1559-0755"],"issn-type":[{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The participant has consented to the submission of the case series to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32"}}